Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGT 002

Next Previous
Drug Profile

BGT 002

Alternative Names: 326E; BGT-002

Latest Information Update: 28 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Burgeon Therapeutics
  • Class Antihyperlipidaemics; Hepatoprotectants; Small molecules
  • Mechanism of Action ATP citrate (pro S) lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-alcoholic steatohepatitis
  • No development reported Hypercholesterolaemia

Most Recent Events

  • 28 Feb 2026 No recent reports of development identified for phase-I development in Hypercholesterolaemia(In volunteers, In adults) in China (PO, Tablet)
  • 18 Jul 2024 Burgeon Therapeutics plans a phase I trial in Hypercholesterolemia (In volunteers) in China (PO)(ChiCTR2200057793)
  • 08 Jun 2024 Pharmacokinetics, efficacy and adverse event data from a phase Ib/II trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver (EASL-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top